Description of Business

12 Months Ended

Dec. 31, 2017

Accounting Policies [Abstract]

Description of Business

Note 1. Description of Business

HTG Molecular Diagnostics, Inc. (the “Company”) is a provider of instruments, reagents and services for molecular profiling applications. The Company derives revenue from sales of its HTG EdgeSeq automation system and integrated next-generation sequencing-based HTG EdgeSeq assays, from services including sample processing and custom research use only (“RUO”) assay development and from collaborative development services.

The Company operates in one segment and its customers are located primarily in the United States and Europe. For the year ended December 31, 2017, approximately 67% of the Company’s revenue was generated from sales originated by customers located outside of the United States, compared with 16% for the year ended December 31, 2016. The increase in sales to customers located outside of the United States is primarily the result of collaborative development services revenue generated from the Master Assay Development, Commercialization and Manufacturing Agreement (the “Governing Agreement”), with QIAGEN Manchester Limited (“QML”), a wholly owned subsidiary of QIAGEN N.V. (See Note 15), which accounted for 80% of sales to customers located outside of the United States.